Great result and especially against gram negative bacteria as my understanding is that is the more difficult target. First significant "real world" data on use in humans and it is shown to treat a resistant strain of bacteria safely and effectively.
Hopefully this result paves the way for other SAS access and results that increase awareness of what this product can do in real world human bacterial infection. Is this the first detail of special access scheme being actually granted?
I wonder if the "stinging" effect will be an issue when used in the burns trial, although I assume patients are under some form of pain treatment anyway and any short term discomfort should be outweighed by the clearing up of resistant bacteria. I guess that kind of feedback is a prime example of the difference between animal trials and human, in that human can describe exactly what they experience. IV trial will be very interesting but surely this case alone already indicates a potential market just for sinusitis which must have value?
RCE Price at posting:
$1.04 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)